Print

Print


Someone on the list was interested in information about migraines.

http://www.reutershealth.com/news/docs/199612/19961223cla.html



     Intranasal Therapy Relieves Migraines

     WESTPORT, Dec 23 (Reuters) - Intranasal administration of
     dihydroergotamine appears to be "...an important new therapeutic
     option for migraine sufferers."

     Dr. R. Michael Gallagher and colleagues from the University of
     Medicine and Dentistry of New Jersey, Moorsetown, explain that
     dihydroergotamine mesylate has long been used in the treatment of
     migraine headaches as a parenterally administered therapy. In the
     current study, they evaluated the efficacy of the drug
     self-administered intranasally at either 2 mg or 3 mg per dose.

     The New Jersey group reports that "...the 2-mg dose provided
     slightly superior efficacy and was associated with fewer adverse
     effects than the 3-mg dose." Specifically, 27% of the patients
     given the 2-mg preparation reported resolution of the migraine
     within 30 minutes of administration, and by 4 hours 70% of the
     patients in the 2-mg treatment arm reported that headaches had
     resolved. This is compared with only 1 in 4 patients on placebo
     whose headaches responded to treatment within 4 hours.

     "Patients treated with dihydroergotamine also experienced
     significantly fewer headache recurrences during the 24-hour
     period after treatment compared with patients using the placebo,"
     according to Dr. Gallagher. Treated patients had significant
     decreases in "...photophobia, phonophobia, nausea and use of
     escape medication."

     The intranasal route of administration in migraine patients has
     several advantages over self-injected medications and over oral
     administration because of nausea and migraine-related gastric
     stasis, the authors say. Dr. Gallagher's team believes that
     dihydroergotamine nasal spray represents a new treatment option
     for patients with migraine.

     Arch Neurol 1996;53:1285-1291.

     -Westport Newsroom 203 221 7648









_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/
_/                                                        _/
_/        Central Supply & Services                       _/
_/        (Internet Training and Research)                _/
_/        PO Box 57247, Jackson Stn.,                     _/
_/        Hamilton, Ontario, Canada, L8P 4X1              _/
_/        John S. Walker                                  _/
_/  Email [log in to unmask]                          _/
_/                                                        _/
_/        "To Teach is to touch a life forever"           _/
_/         On the Web one touch can reach so far!         _/
_/                                                        _/
_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/